Clinical Trials Logo

Filter by:
NCT ID: NCT00338897 Completed - Clinical trials for Venous Thromboembolism

Dose Ranging Study in Elective Total Hip Replacement Surgery

DRIVE
Start date: May 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective is to: - demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE) by the demonstration of a dose-response in patients undergoing total hip replacement surgery. The secondary objectives are to: - evaluate the safety of SR123781A in the prevention of VTE after elective total hip replacement surgery; and - to assess the SR123781A pharmacokinetic profile in patients undergoing elective total hip replacement surgery.

NCT ID: NCT00338078 Completed - Heart Failure Clinical Trials

Nocturnal Oxygen Treatment in Heart Failure and Cheyne-Stokes Respiration

Start date: March 1999
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether oxygen therapy during sleep improves quality of life, exercise capacity and heart function among patients with chronic heart failure and central sleep apnea.

NCT ID: NCT00337090 Completed - Overactive Bladder Clinical Trials

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Start date: n/a
Phase: Phase 2
Study type: Interventional

The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.

NCT ID: NCT00335452 Completed - Angina Unstable Clinical Trials

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

CURRENT/OASIS7
Start date: June 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).

NCT ID: NCT00333866 Completed - Fibromyalgia Clinical Trials

Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.

Start date: July 2006
Phase: Phase 3
Study type: Interventional

This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.

NCT ID: NCT00333840 Completed - Clinical trials for Chronic Myelogenous Leukemia

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Start date: June 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.

NCT ID: NCT00333788 Completed - Crohn's Disease Clinical Trials

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

Welcome2
Start date: October 2006
Phase: Phase 3
Study type: Interventional

The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581]. It will also assess the effect of subcutaneous CDP870 400 mg on direct cost parameters.

NCT ID: NCT00333775 Completed - Breast Cancer Clinical Trials

A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer

Start date: March 2006
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of 2 doses of Avastin in combination with docetaxel, versus docetaxel plus placebo, in patients with metastatic HER2 negative breast cancer who are candidates for taxane-based chemotherapy but who have not received prior chemotherapy for metastatic disease. The anticipated time on treatment is 1-2 years and the target sample size is 500+ individuals.

NCT ID: NCT00333411 Completed - Psoriasis Clinical Trials

Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The purpose of this clinical study is to determine the effectiveness, pharmacokinetics and safety of several doses of BIRT 2584 XX (100mg, 300mg and 500mg) taken once daily in the treatment of moderate to severe plaque-type psoriasis. This new medicine will be compared to a so-called placebo medicine over 12 weeks with a 12 weeks treatment extension possible.

NCT ID: NCT00333073 Completed - Clinical trials for Urinary Incontinence

Effectiveness and Safety of Bulkamid® as Bulking Agent for the Treatment of Female Urinary Incontinence

Start date: March 2006
Phase: N/A
Study type: Interventional

To assess effectiveness of Bulkamid® injection in females suffering from stress or mixed (stress and urge) urinary incontinence after 12 months follow up period